EXECUTING OUR STRATEGY
- Further enhanced organic growth and improved operating margins
- Progression of our late stage pipeline addressing unmet needs including:
- Lifitegrast for dry eye disease and LDX for binge eating and major depressive disorders
- Continued but focused R&D investment in other development opportunities
- Focus on growth and value-driving business development
- Good progress integrating three divisions into a simplified `One Shire'
organization to create operating leverage, drive fast decisions and focus on growth-driving products
Flemming Ornskov, M.D., Chief Executive Officer, commented:
"We are pleased with our Q2 results, have made good progress and have returned to higher growth.
We're successfully executing our strategy, which is to grow by focusing on innovation-driven specialty products through both R&D and M&A. We've sharpened our focus on commercial excellence and we're enhancing our pipeline productivity. Our late Phase 3 projects lifitegrast and LDX for BED are progressing well and are programs in which we have increasing confidence.
Our strategy has been designed to deliver further enhanced growth. We anticipate delivering full year double digit Non GAAP earnings growth in 2013 and are confident in our ability to grow operating margins going forward."
